[Changes in aldosterone and PRA due to the administration of potassium canrenoate in laparotomized patients with liver cirrhosis].
作者信息
Ikebe H, Hoashi S, Irie F, Taniguchi K, Honda N, Mitarai Y, Kobayashi N
出版信息
Masui. 1988 May;37(5):546-51.
PMID:3045361
Abstract
摘要
相似文献
1
2
[Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].口服坎利酸钾与螺内酯治疗原发性高血压疗效的临床研究
Minerva Med. 1983 Apr 7;74(14-15):791-7.
3
4
5
[Effect of potassium canrenoate on arterial pressure, plasma renin activity and urinary aldosterone in essential hypertension].[安体舒通钾对原发性高血压患者动脉血压、血浆肾素活性及尿醛固酮的影响]
Boll Soc Ital Cardiol. 1978;23(10):1757-66.
6
Adaptation to chronic potassium loading in normal man.正常人对慢性钾负荷的适应性
Miner Electrolyte Metab. 1986;12(3):165-72.
7
Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.螺内酯与坎利酸钾的比较临床研究。双交叉随机评估。
Arzneimittelforschung. 1988 Oct;38(10):1492-5.
8
Chronobiological study of factors affecting plasma aldosterone concentration in cirrhosis.
Gastroenterology. 1986 Sep;91(3):683-91. doi: 10.1016/0016-5085(86)90639-6.
9
Sodium excretion and sodium-free volume expansion in dogs: effect of inhibition of aldosterone activity by canrenoate.犬类的钠排泄与无钠容量扩张：坎利酸钾抑制醛固酮活性的作用
Acta Physiol Scand. 1976 Oct;98(2):272-4. doi: 10.1111/j.1748-1716.1976.tb00248.x.
10
Single-dose i.v. Aldactone for congestive heart failure: a preliminary observation.静脉注射单剂量安体舒通治疗充血性心力衰竭：初步观察
Int J Clin Pharmacol Ther Toxicol. 1983 Aug;21(8):417-21.
Zotero 插件